A Rare Clinical Finding of Pseudomyxoma Peritonei in a Case of Abnormal Uterine Bleeding
Keywords:
Pseudomyxoma peritonei, abnormal uterine bleeding, appendicular mass, hysterectomy, HIPEC, case reportAbstract
Pseudomyxoma peritonei (PMP) is a rare condition marked by mucinous ascites and widespread peritoneal tumor deposits, most commonly arising from a perforated mucinous tumor of the appendix. This case report presents an atypical manifestation of PMP in a patient who initially presented with abnormal uterine bleeding. The report highlights the clinical presentation, diagnostic workup, and therapeutic approach.
The patient exhibited progressive abdominal distension, discomfort, and gastrointestinal symptoms. Diagnostic confirmation was achieved through detailed clinical evaluation, radiological imaging, and histopathological analysis. Surgical management involved cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC), which significantly enhanced the patient's prognosis.
Although PMP is uncommon, early recognition and prompt intervention are critical for improving outcomes. The combined approach of cytoreductive surgery and HIPEC remains the current gold standard in treatment. This case emphasizes the need for heightened clinical suspicion and a coordinated, multidisciplinary strategy to achieve optimal patient care
Downloads
References
Albright J, McMullin N, Morgan MA. Pseudomyxoma peritonei presenting as an adnexal mass: a case report and literature review. J Obstet Gynaecol Can. 2011;33(11):1171–1175.
Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population-based study. Eur J Surg Oncol. 2008;34(2):196–201.
Esquivel J, Sugarbaker PH. Clinical presentation of pseudomyxoma peritonei syndrome. Br J Surg. 2000;87(10):1414–1418.
Pranesh N, Jayson GC. Pseudomyxoma peritonei. Curr Oncol Rep. 2002;4(6):448–453.
Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases. Am J Surg Pathol. 1995;19(12):1390–1408.
Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg. 1999;384(6):576–587.
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei treated by cytoreductive surgery and HIPEC. J Clin Oncol. 2012;30(20):2449–2456.
Elias D, Gilly FN, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with CRS and HIPEC. Ann Surg Oncol. 2010;17(3):827–835.
Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a review of 2,298 patients. J Surg Oncol. 2009;100(8):529–533.
Baratti D, Kusamura S, Nonaka D, et al. Serum tumor markers as early predictors of outcome in PMP treated with CRS and HIPEC. Ann Surg Oncol. 2007;14(8):2300–2308.
Klemm P, Schwarzbach M, Hünerbein M, Schlag PM. The role of imaging in follow-up of patients with pseudomyxoma peritonei. Eur Radiol. 2005;15(7):1393–1400.
Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia. Am J Surg Pathol. 2016;40(1):14–26.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
